Ergoteles’s Aprea Therapeutics APRE Stock Holding History

Ergoteles’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-929	Closed	-$91K	–	1183
2021 Q2	$91K	Buy	+929	New	+$85.8K	﹤0.01%	1421

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles's APRE Position: Q3 2021 in Review

Ergoteles sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 929 shares — an estimated $91K sold.

Ergoteles first reported a position in APRE in Q2 2021 and held it in 1 quarter. The position peaked at $91K in Q2 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

Ergoteles reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 929 Aprea Therapeutics shares in Q3 2021, an estimated $91K.
Ergoteles first reported a position in Aprea Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Aprea Therapeutics position peaked at $91K in Q2 2021.
39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.